Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Coherus Oncology (CHRS) over the last 13 years, with Q2 2025 value amounting to -$483.4 million.

  • Coherus Oncology's Capital Expenditures fell 110850.0% to -$483.4 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$478.7 million, marking a year-over-year decrease of 11014.23%. This contributed to the annual value of $286000.0 for FY2023, which is 8597.35% down from last year.
  • Latest data reveals that Coherus Oncology reported Capital Expenditures of -$483.4 million as of Q2 2025, which was down 110850.0% from $4.7 million recorded in Q1 2025.
  • Coherus Oncology's 5-year Capital Expenditures high stood at $4.7 million for Q1 2025, and its period low was -$483.4 million during Q2 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $152000.0 (2023), whereas its average is -$46.9 million.
  • Per our database at Business Quant, Coherus Oncology's Capital Expenditures soared by 32413.79% in 2022 and then plummeted by 12366776.32% in 2024.
  • Over the past 5 years, Coherus Oncology's Capital Expenditures (Quarter) stood at $468000.0 in 2021, then crashed by 81.41% to $87000.0 in 2022, then plummeted by 60.92% to $34000.0 in 2023, then plummeted by 117747.06% to -$40.0 million in 2024, then tumbled by 1108.5% to -$483.4 million in 2025.
  • Its Capital Expenditures was -$483.4 million in Q2 2025, compared to $4.7 million in Q1 2025 and -$40.0 million in Q2 2024.